A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-B12)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04739761 |
Recruitment Status :
Completed
First Posted : February 5, 2021
Last Update Posted : February 20, 2024
|
Sponsor:
AstraZeneca
Collaborator:
Daiichi Sankyo
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | February 8, 2024 |
Actual Study Completion Date : | February 8, 2024 |